Our research group is embedded within the Translational Research Unit – Infectious Diseases (TRU-ID) at the Center for Molecular Medicine Cologne (CMMC) with highest standard laboratories covering biosafety levels (BSL) 1 to 3. Focus of our research group is to develop new innovative immunotherapies to improve treatment of severe bacterial infections, which are still responsible for a high morbidity and mortality worldwide. Key aspect of our work is to design and modify monoclonal antibodies that specifically target bacterial pathogens.
A highly progressive, diverse, and innovative scientific environment is provided by the strong relations within the University of Cologne as well as to other national and international research groups. The appointee will be enabled to conduct own research projects with an upmost creativity and intellectual freedom.